Alliance for Pandemic Preparedness

June 8, 2021

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

Category:

Topic:

Keywords (Tags):

  • The risk of any SARS-CoV-2 infection was reduced by 51% between 13 to 24 days after the first dose of the Pfizer-BioNTech vaccine when compared to a period of 1 to 12 days after vaccination, according to a comparative effectiveness study in Israel (n=503,875). The weighted daily incidence of SARS-CoV-2 infection decreased from 43.4 infections per 100,000 in days 1 through 12 to 21.1 infections per 100,000 in days 13 to 24, with similar decreases across age and sex subgroups. Overall single-dose vaccine effectiveness against symptomatic COVID-19 was 54.4%.

Chodick et al. (June 7, 2021). Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.15985